Combined Use Of Atacand(R) And ACE Inhibitor Improves Heart Failure Outcomes More Than ACE Inhibitor Alone

... (NYSE:AZN) today announced the publication of a supplemental analysis from theCandesartan in Heart failure: Assessment of Reduction in Mortality andMorbidity (CHARM)-Added trial in the May issue of the American HeartJournal. This analysis provides evidence that the clinical benefits ofATACAND in reducing the risk of cardiovascular death and heart failurehospitalizations in patients with symptomatic heart failure and reducedheart pump function were not modified by baseline dose of ACE inhibitor,beta-blocker use at baseline, or ACE inhibitor dose during the trial... click link for more info. ...